RxDoctor Payments Data

Leah Franks, PA

Physician Assistant · Moneta, VANPI 1811937113

Payments from drug & device makers

$1,614in general payments, 2019–2025

Across 43 payments — averaging $37.54 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$342
  • Astellas Pharma US Inc$311
  • Urovant Sciences Inc$170
  • Medtronic$123
  • Myovant Sciences Inc.$115
  • Rigel Pharmaceuticals, Inc.$100
  • plus $455 from 11 others

What the payments were for

  • Food & beverage$1,52995%
  • Education$855%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,614 in reported general payments places this provider in the 80th percentile of 3,376 physician assistant providers in Virginia.

See all physician assistant providers in Virginia

Medicare billing

Part B allowed, 2024
$57,337
Medicare patients
178
Services billed
716

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MyrbetriqMirabegron29$6,663
Gabapentin61$1,132
Ondansetron OdtOndansetron55$903
Oxycodone Hcl29$833
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen33$803
Fentanyl11$794
Pregabalin14$677
Donepezil Hcl30$655
Ondansetron Hcl19$435
Hydroxyurea11$386
Prochlorperazine Maleate27$242
Lorazepam15$239
Lidocaine-PrilocaineLidocaine/Prilocaine16$202
Duloxetine Hcl11$154
Diphenoxylate-AtropineDiphenoxylate Hcl/Atropine12$122

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncMyrbetriq$311$6,66329 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 3,376 physician assistant providers in Virginia.

Other physician assistant in Moneta

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →